{
  "patient_id": "SA-P006",
  "documents": [
    {
      "visit_number": 1,
      "date": "2025-07-01",
      "type": "progress_note",
      "text": "--- Visit 1 | Date: 2025-07-01 ---\n\nRoutine protocol visit 1. Patient ID: SA-P006.\n\nVital signs obtained: blood pressure 148/94, heart rate 68, weight 87.8 kg.\n\nBlood work results:\n  - PSA: 4.35 ng/mL [ref 0.0-4.0] (HIGH)\n  - ALT: 16.27 U/L [ref 7.0-56.0]\n  - AST: 1.65 U/L [ref 10.0-40.0] (LOW)\n  - Hemoglobin: 13.5 g/dL [ref 12.0-17.5]\n  - WBC: 4.86 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 0.92 mg/dL [ref 0.7-1.3]\n\nPlan: Continue current regimen. Follow up in 3 weeks.\n"
    },
    {
      "visit_number": 2,
      "date": "2025-07-22",
      "type": "progress_note_with_imaging",
      "text": "--- Visit 2 | Date: 2025-07-22 ---\n\nSA-P006 \u2014 Cycle 2, Day 1 visit.\n\nOn exam, BP is 122/86, pulse 87, wt 82.3 kg. Patient appears slightly pale but hemodynamically stable.\n\nNo new adverse events reported since last visit.\n\nBlood work results:\n  - PSA: 4.99 ng/mL [ref 0.0-4.0] (HIGH)\n  - ALT: 13.55 U/L [ref 7.0-56.0]\n  - AST: 4.57 U/L [ref 10.0-40.0] (LOW)\n  - Hemoglobin: 14.01 g/dL [ref 12.0-17.5]\n  - WBC: 3.99 10^3/uL [ref 4.5-11.0] (LOW)\n  - Creatinine: 0.85 mg/dL [ref 0.7-1.3]\n\nImaging: Target lesion measurements stable \u2014 neither sufficient shrinkage for PR nor increase for PD. Classified as stable disease (SD) per RECIST.\n\nPSA now 9.97 ng/mL \u2014 decrease 6.8% from initial value.\n\nContinue study protocol. Monitor labs. Return visit 3 scheduled in 3 weeks.\n"
    },
    {
      "visit_number": 3,
      "date": "2025-08-12",
      "type": "progress_note",
      "text": "--- Visit 3 | Date: 2025-08-12 ---\n\nFollow-up visit #3 for patient SA-P006.\n\nVital signs obtained: blood pressure 120/77, heart rate 88, weight 85.3 kg.\n\nPatient reports moderate diarrhea beginning day 63. Currently ongoing. Study drug dose was reduced per protocol guidelines.\nmoderate neutropenia detected. CTCAE Grade 2, onset day 62. Resolved by day 80. Patient monitored closely. No dose modification required.\n\nBlood work results:\n  - PSA: 3.92 ng/mL [ref 0.0-4.0]\n  - ALT: 17.67 U/L [ref 7.0-56.0]\n  - AST: 3.7 U/L [ref 10.0-40.0] (LOW)\n  - Hemoglobin: 13.1 g/dL [ref 12.0-17.5]\n  - WBC: 4.4 10^3/uL [ref 4.5-11.0] (LOW)\n  - Creatinine: 0.95 mg/dL [ref 0.7-1.3]\n\nPlan: Monitor closely and reassess at next visit. Return for cycle 4 in 3 weeks.\n"
    },
    {
      "visit_number": 4,
      "date": "2025-09-02",
      "type": "progress_note_with_imaging",
      "text": "--- Visit 4 | Date: 2025-09-02 ---\n\nPatient SA-P006 presents for scheduled cycle 4 visit.\n\nVS: 105/94 | HR 77 | Wt 75.6 kg. Patient slightly pale but hemodynamically stable.\n\nLaboratory results:\n  - PSA: 3.24 ng/mL [ref 0.0-4.0]\n  - ALT: 17.92 U/L [ref 7.0-56.0]\n  - AST: 4.42 U/L [ref 10.0-40.0] (LOW)\n  - Hemoglobin: 12.91 g/dL [ref 12.0-17.5]\n  - WBC: 3.68 10^3/uL [ref 4.5-11.0] (LOW)\n  - Creatinine: 0.97 mg/dL [ref 0.7-1.3]\n\nCT restaging shows partial response. Target lesions reduced significantly (39.4% decrease from baseline). No new lesions identified. RECIST: PR.\n\nPSA level is 6.48 ng/mL (decrease 39.4% from baseline).\n\nPlan: Monitor closely and reassess at next visit. Return for cycle 5 in 3 weeks.\n"
    },
    {
      "visit_number": 5,
      "date": "2025-09-23",
      "type": "progress_note",
      "text": "--- Visit 5 | Date: 2025-09-23 ---\n\nFollow-up visit #5 for patient SA-P006.\n\nVS: 125/92 | HR 75 | Wt 65.2 kg. Patient well-nourished and in no acute distress.\n\nPatient reports Thrombocytopenia (moderate, Grade 2). First noted day 88. Currently ongoing. No dose modification required.\n\nBlood work results:\n  - PSA: 3.86 ng/mL [ref 0.0-4.0]\n  - ALT: 19.55 U/L [ref 7.0-56.0]\n  - AST: 6.36 U/L [ref 10.0-40.0] (LOW)\n  - Hemoglobin: 13.07 g/dL [ref 12.0-17.5]\n  - WBC: 3.47 10^3/uL [ref 4.5-11.0] (LOW)\n  - Creatinine: 0.95 mg/dL [ref 0.7-1.3]\n\nAssessment: Tolerating therapy. Plan to continue protocol. Next visit in 3 weeks.\n"
    },
    {
      "visit_number": 6,
      "date": "2025-10-14",
      "type": "progress_note_with_imaging",
      "text": "--- Visit 6 | Date: 2025-10-14 ---\n\nPatient SA-P006 presents for scheduled cycle 6 visit.\n\nVS: 131/91 | HR 67 | Wt 82.3 kg. Patient comfortable, no distress noted.\n\nNo new adverse events reported since last visit.\n\nLabs drawn today:\n  - PSA: 2.88 ng/mL [ref 0.0-4.0]\n  - ALT: 19.23 U/L [ref 7.0-56.0]\n  - AST: 5.91 U/L [ref 10.0-40.0] (LOW)\n  - Hemoglobin: 12.91 g/dL [ref 12.0-17.5]\n  - WBC: 2.81 10^3/uL [ref 4.5-11.0] (LOW)\n  - Creatinine: 0.98 mg/dL [ref 0.7-1.3]\n\nImaging: Target lesion measurements stable \u2014 neither sufficient shrinkage for PR nor increase for PD. Classified as stable disease (SD) per RECIST.\n\nPSA now 10.23 ng/mL \u2014 decrease 4.4% from initial value.\n\nContinue study protocol. Monitor labs. Return visit 7 scheduled in 3 weeks.\n"
    },
    {
      "visit_number": 7,
      "date": "2025-11-04",
      "type": "progress_note",
      "text": "--- Visit 7 | Date: 2025-11-04 ---\n\nSA-P006 \u2014 Cycle 7, Day 1 visit.\n\nOn exam, BP is 138/74, pulse 63, wt 96.1 kg. Patient appears mildly fatigued but alert and oriented.\n\nAdverse event noted: Headache \u2014 mild (CTCAE Grade 1). Onset day 127. Currently ongoing. Assessed as probable to study drug. No dose modification required.\n\nBlood work results:\n  - PSA: 3.14 ng/mL [ref 0.0-4.0]\n  - ALT: 19.09 U/L [ref 7.0-56.0]\n  - AST: 5.97 U/L [ref 10.0-40.0] (LOW)\n  - Hemoglobin: 12.69 g/dL [ref 12.0-17.5]\n  - WBC: 3.02 10^3/uL [ref 4.5-11.0] (LOW)\n  - Creatinine: 0.98 mg/dL [ref 0.7-1.3]\n\nPlan: Continue current regimen. Follow up in 3 weeks.\n"
    },
    {
      "visit_number": 8,
      "date": "2025-11-25",
      "type": "progress_note_with_imaging",
      "text": "--- Visit 8 | Date: 2025-11-25 ---\n\nPatient SA-P006 presents for scheduled cycle 8 visit.\n\nVitals: BP 117/88 mmHg, HR 62 bpm, Weight 74.0 kg.\n\nLabs drawn today:\n  - PSA: 2.34 ng/mL [ref 0.0-4.0]\n  - ALT: 20.68 U/L [ref 7.0-56.0]\n  - AST: 7.46 U/L [ref 10.0-40.0] (LOW)\n  - Hemoglobin: 12.84 g/dL [ref 12.0-17.5]\n  - WBC: 2.73 10^3/uL [ref 4.5-11.0] (LOW)\n  - Creatinine: 1.01 mg/dL [ref 0.7-1.3]\n\nImaging assessment: Target lesion decreased from baseline \u2014 measured reduction of approximately 25.2%. Partial response per RECIST 1.1 criteria.\n\nPSA now 8.0 ng/mL \u2014 decrease 25.2% from initial value.\n\nPlan: Continue current dose. Return for cycle 9 in 3 weeks.\n"
    }
  ]
}